Streetbeat News

Stock Prices

LRCX

A whale investor has taken a bearish stance on Lam Research (NASDAQ:LRCX), with 72% of the investors opening trades with bearish expectations. The whales have been targeting a price range from $490.0 to $750.0 for Lam Research over the last 3 months. The price of LRCX is down -1.35% at $654.7. Stifel has maintained their Buy rating on Lam Research, with a price target of $750.

Portfolio Pulse from Benzinga Insights

September 12, 2023 | 6:46 pm

AVTX

CGNT

DTSS

ORCL

SGHT

SLRN

TNON

US stocks traded mostly lower with the Nasdaq Composite falling over 100 points. Energy shares jumped by 2.4%. Oracle Corporation's shares fell around 12% after releasing first-quarter results. Tenon Medical, Avalo Therapeutics, and Cognyte Software shares rose significantly. Acelyrin, Sight Sciences, and Datasea shares dropped significantly. Oil traded up 2% while gold traded down 0.6%.

Portfolio Pulse from Lisa Levin

September 12, 2023 | 6:44 pm

BMY

GERN

Goldman Sachs has upgraded Geron Corporation (GERN) to Buy from Neutral, with a price target of $4. The FDA has assigned a standard review and a PDUFA action date of June 16, 2024, for Geron's New Drug Application for imetelstat. The FDA plans to hold an advisory committee meeting. The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for imetelstat. The recent pullback in GERN shares has presented a buying opportunity.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 6:43 pm

WE

WeWork Inc. (NYSE:WE) shares surged nearly 50% on heavy trading volume, with over 26 million shares traded in the session, compared to the average volume of 1.354 million shares. Despite the surge, WeWork shares remain down nearly 40% over the last month. The company, which effected a 1-for-40 reverse stock split on Sept. 1, has become a popular 'meme stock' among retail investors.

Portfolio Pulse from Erica Kollmann

September 12, 2023 | 6:41 pm

NIO

NIO Inc. (NYSE:NIO) shares are trading higher due to the upcoming release of its newest electric vehicle, the EC6, on September 15. The new EC6 SUV EVs have already arrived at Nio's showrooms and test drives will be available starting on the release date. Despite a 20% drop over the last month, NIO's stock remains up more than 35% over the last three months.

Portfolio Pulse from Erica Kollmann

September 12, 2023 | 6:40 pm

AAPL

QCOM

Apple Inc. has announced the iPhone 15 series, featuring a USB-C port, periscope camera, and more. The iPhone 15 price starts at $799, with the top-tier iPhone 15 Pro Max price starting at $1,199. The new phones also feature a 48MP primary camera, a Dynamic Island replacing the boat-shaped notch, and a customizable Action button. The iPhone 15 and iPhone 15 Plus are powered by the A16 Bionic chipset, while the iPhone 15 Pro and iPhone 15 Pro Max get a new A17 Pro silicon. Apple also uses Qualcomm Inc.'s modem.

Portfolio Pulse from Rounak Jain

September 12, 2023 | 6:35 pm

ETSY

Tim Riegel, owner of Mozark Fire Pit Studio, has managed to maintain strong sales despite inflationary pressures. His business, which sells heavy steel fire pits via Etsy Inc (NASDAQ:ETSY), has generated $169,000 in sales over the past year, despite rising costs of recyclable steel, gas, and packaging. Riegel has managed to offset these costs by incrementally increasing prices and offering more customization options.

Portfolio Pulse from AJ Fabino

September 12, 2023 | 6:34 pm

NBIX

Neurocrine Biosciences Inc (NASDAQ:NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH). The study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically significant reduction in daily glucocorticoid dose versus placebo. The company's shares are up 7.82% at $118.21.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 6:33 pm

HUMA

Regenerative medicine firm Humacyte Inc (NASDAQ:HUMA) has released promising topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair. The HAV showed higher rates of patency and lower rates of amputation and infection than historic synthetic graft benchmarks. Humacyte plans to file a Biologics License Application for vascular trauma with the FDA during Q4 of 2023. Following the news, HUMA shares are up 8.11% at $4.00.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 6:31 pm

ALGN

Align Tech (NASDAQ:ALGN) has outperformed the market over the past 15 years, producing an average annual return of 24.35%. If an investor had bought $100 of ALGN stock 15 years ago, it would be worth $2,470.23 today. The company currently has a market capitalization of $25.05 billion.

Portfolio Pulse from Benzinga Insights

September 12, 2023 | 6:30 pm